CircIFNGR2 Enhances Proliferation and Migration of CRC and Induces Cetuximab Resistance by Indirectly Targeting KRAS via Sponging to MiR-30b

To study the mechanism of cetuximab resistance in KRAS wild-type colorectal cancer (CRC) patients, scientists evaluated the impact of circIFNGR2 on CRC and detected the association among circIFNGR2, miR-30b, and KRAS via various experiments such as RT-qPCR, immunohistochemistry, luciferase assays, cell functional experiments and xenograft model.